Skip to main navigation Skip to search Skip to main content

QWINT-4: A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabetes on Multiple Display Injectio

Project: Research

Project Details

StatusFinished
Effective start/end date09/21/22 → 12/31/25

Funding

  • Lilly USA LLC: $271,580.00